Pharmaceuticals News and Research

RSS

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the U.S. Patent & Trademark Office has issued a Notice of Allowance to the Company for an important manufacturing method patent for its drug candidate CF101.

10 Jun 2015

Lynden International selects Cryoport as preferred cryogenic logistics provider

Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that it has been selected by Lynden International as its preferred provider to support cold chain clinical trial logistics for underrepresented diseases in Africa.

10 Jun 2015

Catalan researchers first to use liposomes to fight against diabetes

For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.

10 Jun 2015

RFID smart cabinet systems make headway into healthcare

Radio frequency identification (RFID) is rapidly making headway into the healthcare and pharmaceutical industries, especially in assets tracking, supply chain management, and inventory management. In particular, the need for inventory management to reduce instances of loss or misplacement of medical equipment, supplies or drugs, along with efforts to minimise errors and improve patient safety, drives the market for RFID smart cabinet systems.

10 Jun 2015

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

10 Jun 2015

New microfluidic chip could save millions of euros in drug development costs

Scientists in an EU-supported project have developed a microfluidic chip that simultaneously analyses the reactions of several human organ tissues when they come into contact with candidates for new drugs.

10 Jun 2015

$Full clinical trial feasible in refractory chronic angina pectoris$

Full clinical trial feasible in refractory chronic angina pectoris

Results of the world's first publicly funded randomized controlled clinical trial of spinal cord stimulation, being presented today at the 12th World Congress of the International Neuromodulation Society, conclude that a fully powered clinical trial is feasible in refractory chronic angina pectoris, a disabling and persistent chronic pain condition.

10 Jun 2015

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.

10 Jun 2015

Kaiser Permanente study identifies barriers to prescribing potentially life-saving medication

A variety of factors including questions about risk and reluctance to offend patients limits clinician willingness to prescribe a potentially life-saving medication that counteracts the effects of an opioid overdose, according to a Kaiser Permanente Colorado study published today in the Journal of General Internal Medicine.

10 Jun 2015

PharmApprove, NDA Group partner to help life science companies navigate complex global environment

Two leading drug development and regulatory consultancies announced today that they have formed a new strategic alliance to help life science companies navigate an increasingly complex global environment.

10 Jun 2015

UK scientists explore the impact of antibiotic resistant bacteria on surfers

UK Scientists are about to begin an innovative study that will shed light on how surfers exposed to human sewage and diffuse pollution in seawater might be affected by antibiotic resistant bacteria.

10 Jun 2015

OSU microbiologists discover new type of dairy or food thickener with probiotic characteristics

Microbiologists at Oregon State University have discovered and helped patent and commercialize a new type of dairy or food thickener, which may add probiotic characteristics to the products in which it's used.

10 Jun 2015

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure.

10 Jun 2015

Researchers develop mesoporous particles for use as drug delivery system

A research group led by MANA Scientist Kohsaku Kawakami, postdoctoral researcher Shaoling Zhang and MANA Principal Investigator Katsuhiko Ariga, at the International Center for Materials Nanoarchitectonics (MANA), NIMS (Sukekatsu Ushioda, President), succeeded in developing porous particles (mesoporous particles) consisting solely of phospholipids, a biological component, that are suitable for use as a drug delivery system.

10 Jun 2015

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.

10 Jun 2015

Scientists study crystallisation process to find new ways to produce pharmaceuticals

Scientists from across the UK and Europe are working together to build a better understanding of the chemical processes behind the creation of crystals with the aim of developing new ways to produce pharmaceuticals.

10 Jun 2015

BiOptix to release advances in protein engineering research at AAPS National Biotech Conference

BiOptix, a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions, today announced the release of a new study on the biophysical analysis of biotherapeutics done in collaboration with Indiana University, the National Defense Science and Engineering Graduate Fellowship and the National Institute of Allergy and Infectious Disease.

10 Jun 2015

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of the investigational therapy Praluent (alirocumab) Injection.

9 Jun 2015

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Ampio Pharmaceuticals, Inc. today announced three peer-review publications that report the multifaceted and synergistic effects of Ampion in the treatment of osteoarthritis in the knee.

9 Jun 2015

Lycera forms exclusive global collaboration with Celgene

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the formation of an exclusive global collaboration with Celgene Corporation to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases.

9 Jun 2015

Pharmaceuticals News and Research

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Lynden International selects Cryoport as preferred cryogenic logistics provider

Catalan researchers first to use liposomes to fight against diabetes

RFID smart cabinet systems make headway into healthcare

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

New microfluidic chip could save millions of euros in drug development costs

Full clinical trial feasible in refractory chronic angina pectoris

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

Kaiser Permanente study identifies barriers to prescribing potentially life-saving medication

PharmApprove, NDA Group partner to help life science companies navigate complex global environment

UK scientists explore the impact of antibiotic resistant bacteria on surfers

OSU microbiologists discover new type of dairy or food thickener with probiotic characteristics

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

Researchers develop mesoporous particles for use as drug delivery system

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Scientists study crystallisation process to find new ways to produce pharmaceuticals

BiOptix to release advances in protein engineering research at AAPS National Biotech Conference

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Lycera forms exclusive global collaboration with Celgene

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring